Double-Blind NT-I7 for COVID-19

"Affirmative. Clinicaltrials.gov contains evidence that this research trial, initially posted on November 27th 2020, is in search for 30 patients from 2 different sites."

"The eligibility requirements for this research project set the age range from 19 to 75. For minors under 18, there are 137 trials available and 910 options exist for those aged 65 or above."

"This study is enrolling 30 individuals with COVID-19 who are aged between 19 and 75. In order to be eligible, applicants must abide by the following criteria: not partake in any other clinical trial for an investigational therapy within a month of applying; oxygen saturation exceeding 93% at rest; heart rate no more than 100 beats per minute when stationary; respiration rate beneath 20 breaths per minute without exhibiting respiratory distress."

"Given the Phase 1 nature of this trial, our team at Power estimated that Double-Blind NT-I7 is relatively low risk with a rating of 1. This indicates minimal clinical data backing safety and efficacy claims."

"In 2018, Double-Blind NT-I7 was initially studied at UCSF Comprehensive Cancer Center. Since then, 1 trial has been completed with 11 additional studies actively recruiting patients. These active investigations are largely based in Bethesda, Maryland."

"Based on information available from clinicaltrials.gov, this medical trial is currently open for enrollment - it was first posted on the 27th of November 2020 and has since been updated as recently as September 26th 2022."

"Currently, 11 different clinical trials for Double-Blind NT-I7 are open in 39 cities across four countries. NeoImmuneTech initiated the first trial of its kind back in 2018 with 12 participants; it successfully completed Phase 1 drug approval and has since concluded."